PMID- 32218828
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 19
IP  - 4
DP  - 2020 Apr
TI  - Expression of Foxp3 and interleukin-7 receptor and clinicopathological 
      characteristics of patients with diffuse large B-cell lymphoma.
PG  - 2755-2764
LID - 10.3892/ol.2020.11374 [doi]
AB  - The most specific biomarker on the surface of regulatory T cells (Tregs) is the 
      forkhead/wingeded-helix protein 3 (Foxp3). In contrast, the expression of 
      interleukin-7 receptor (IL-7R) is low or negative in Tregs. The present study 
      aimed to investigate the expression of Foxp3 and IL-7R in diffuse large B-cell 
      lymphoma (DLBCL), and to analyse the clinicopathological characteristics of 
      patients with DLBCL and their association with overall survival (OS). 
      Immunohistochemistry was performed to detect the expression of Foxp3 and IL-7R on 
      routinely processed formalin-fixed and paraffin-embedded specimens. The chi(2) test 
      was used to analyse the association between the expression of Foxp3 and IL-7R and 
      the clinicopathological characteristics of patients with DLBCL. Survival curves 
      were used to investigate the effect of Foxp3 and IL-7R on patient prognosis. The 
      results demonstrated that high Foxp3 expression in tissue was associated with 
      non- germinal centre B-cell (GCB)-type disease (P=0.012), International 
      Prognostic Index score >0 (P=0.012), stage 3 or 4 tumour (P=0.045) and disease 
      progression and stabilization period (P=0.032). In addition, IL-7R expression was 
      associated with non-GCB-type disease (P=0.001) and extranodal lymphoma (P=0.008). 
      Furthermore, expression of Foxp3 and IL-7R was not associated with OS (P=0.447 
      and P=0.201, respectively). Foxp3 and IL-7R expression in non-GCB-type lymphoma 
      was significantly higher compared with that in GCB lymphoma. The expression of 
      Foxp3 and IL-7R may therefore help the development of individualized treatment, 
      prognostic prediction and therapy stratification.
CI  - Copyright: (c) Zhao et al.
FAU - Zhao, Yan
AU  - Zhao Y
AD  - Department of Pathology, The First Affiliated Hospital, Xinjiang Medical 
      University, Xinjiang, Urumqi 830011, P.R. China.
FAU - Cui, Wen-Li
AU  - Cui WL
AD  - Department of Pathology, The First Affiliated Hospital, Xinjiang Medical 
      University, Xinjiang, Urumqi 830011, P.R. China.
FAU - Feng, Zhi-Yin
AU  - Feng ZY
AD  - Department of Pathology, The First Affiliated Hospital, Xinjiang Medical 
      University, Xinjiang, Urumqi 830011, P.R. China.
FAU - Xue, Jing
AU  - Xue J
AD  - Department of Pathology, The First Affiliated Hospital, Xinjiang Medical 
      University, Xinjiang, Urumqi 830011, P.R. China.
FAU - Gulinaer, Abulajiang
AU  - Gulinaer A
AD  - Department of Pathology, The First Affiliated Hospital, Xinjiang Medical 
      University, Xinjiang, Urumqi 830011, P.R. China.
FAU - Zhang, Wei
AU  - Zhang W
AD  - Department of Pathology, The First Affiliated Hospital, Xinjiang Medical 
      University, Xinjiang, Urumqi 830011, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20200206
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC7068468
OTO - NOTNLM
OT  - clinicopathological analysis
OT  - diffuse large B-cell lymphoma
OT  - forkhead/winged-helix protein 3
OT  - immunological targets
OT  - interleukin-7 receptor
EDAT- 2020/03/29 06:00
MHDA- 2020/03/29 06:01
PMCR- 2020/02/06
CRDT- 2020/03/29 06:00
PHST- 2019/05/15 00:00 [received]
PHST- 2020/01/08 00:00 [accepted]
PHST- 2020/03/29 06:00 [entrez]
PHST- 2020/03/29 06:00 [pubmed]
PHST- 2020/03/29 06:01 [medline]
PHST- 2020/02/06 00:00 [pmc-release]
AID - OL-0-0-11374 [pii]
AID - 10.3892/ol.2020.11374 [doi]
PST - ppublish
SO  - Oncol Lett. 2020 Apr;19(4):2755-2764. doi: 10.3892/ol.2020.11374. Epub 2020 Feb 
      6.